Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

r survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release anticipating future clinical and business prospects for our lead drug candidate Sulonex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the results of the Phase 3 study for Sulonex could be inconclusive or negative; even if we receive positive results from the Phase 3 study for Sulonex, we may not be able to finalize the NDA before year end for various reasons including the completion of necessary non- clinical studies; the completion of manufacturing preparations; or other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

Keryx Contact:

Lauren Fischer

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
(Date:5/29/2015)... 29, 2015  Excite Medical was established by its ... years, Excite Medical, under the leadership of Mr. ... with a solid track record of providing unparalleled service ... distributor base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... has been possible, in large part, due to ...
(Date:5/29/2015)... BRUNSWICK, N.J. , May 29, 2015 ... start-up companies originally funded with investments from Foundation Venture ... research at Bio International 2015 as part of the ... Conference, announced FVCG President James M. Golubieski . ... for the biotechnology industry, will be held in ...
Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 2Foundation Venture Capital Group Portfolio Companies to be Highlighted at Bio International in June 3
... Oct. 11 Essentialis, Inc. announced today that the ... has issued U.S. Patent No. 7,799,777 entitled Salts ... The patent claims a novel composition of a polymorph ... lead product, DCCR.  Essentialis has successfully completed phase 2b ...
... 11 Pioneer Surgical Technology, Inc., a leader ... plan to establish a manufacturing and distribution facility ... IDA (Ireland Development Authority) to evaluate potential sites ... facility will support Pioneer,s continued growth in Europe ...
Cached Medicine Technology:Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio 2PioneerĀ® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland 2
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
(Date:5/30/2015)... Michigan (PRWEB) May 30, 2015 NovaSure® ... to lighten or stop periods, without the side ... procedure can reduce or stop menstrual bleeding and works ... uterus (the part that causes the bleeding), with a ... women suffer from heavy menstrual bleeding. Many women ...
(Date:5/30/2015)... San Diego, CA (PRWEB) May 30, 2015 ... public is the lack of local healthcare options available. ... access to adequate healthcare. For those in rural areas ... those simply without health insurance or tired of paying ... announces new E-consults, connecting patients with licensed physicians via ...
(Date:5/30/2015)... New York (PRWEB) May 30, 2015 ... pay $100 million in punitive and compensatory damages ... plaintiff who suffered serious complications following implantation of ... to a verdict rendered on May 28th in ... million in compensatory damages after the jury found ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4
... ... in a new, or remodeled home, built between 2004, and 2008, in ... numerous air conditioning problems, combined with health issues, the Chinese Drywall Complaint ... toxic Chinese drywall being the culprit. The new major focus areas are ...
... ... selected the Atlanta-based IT support and service company to manage IT services and hosting ... ... Atlanta’s fastest growing managed IT services company, announced today that Marietta Eye Clinic ...
... ... CellTrak’s latest clients, Community Home Support Services Association (CHSSA) supports elderly ... CHSSA provides a variety of health care services during in-home client ... were recorded on paper along with older technologies, like voicemail, copies ...
... WEEKEND ADMISSION TO ICU MAY INCREASE RISK OF DEATH ... may have an increased risk of death compared with ... of Philadelphia, Philadelphia, PA, and Eastern Virginia Medical School, ... association between time of admission to the ICU and ...
... Abuse and neglect during childhood appear to be associated with ... young adults, according to a report in the June issue ... JAMA/Archives journals. Most studies of child maltreatment and later ... according to background information in the article. Doubts have been ...
... MONDAY, July 5 (HealthDay News) -- Too much time spent ... of attention problems in children and young adults, new research ... point out the ill effects of excessive screen time, whether ... a graduate student at Iowa State University, compared participants who ...
Cached Medicine News:Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 2Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 3Health News:Chinese Drywall Complaint Center Will Assist Homeowners In Tampa, Orlando, Houston, Austin & Montgomery Discover If They Have Knauf Chinese Drywall 4Health News:Marietta Eye Clinic Selects BlueWave Computing for IT Support and Hosting 2Health News:Marietta Eye Clinic Selects BlueWave Computing for IT Support and Hosting 3Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 2Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 3Health News:CellTrak Mobile Technology Improves Client Care in Vancouver for the Community Home Support Services Association 4Health News:News briefs from the July issue of Chest 2Health News:Abused children appear likely to have mental disorders as young adults 2Health News:Too Much Screen Time Can Threaten Attention Span 2Health News:Too Much Screen Time Can Threaten Attention Span 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: